findmyKOL

Guillermo Garcia-Manero, MD

Enriched profile

Chair Ad Interim, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center · The University of Texas MD Anderson Cancer Center

ORCIDNPI
Region🇺🇸 Houston, TX · South Central · United StatesSpecialtyMedical OncologyFocusAcute Myeloid Leukemia Research+4
Active KOLEmergingfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2004–2008

Guillermo Garcia-Manero is Chair Ad Interim, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 2,993 publications with 90,546 citations (h-index 150); ClinicalTrials.gov lists 25 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Guillermo Garcia-Manero as a Highly Cited Researcher (Clinical Medicine, 2015-2016, 2018-2020, 2024).

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Guillermo Garcia-Manero, M.D., is Chair Ad Interim, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center. The public record shows 2,993 publications with 90,546 citations (h-index 150), centered on Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Myeloproliferative Neoplasms: Diagnosis and Treatment. It also documents an investigator role on 25 registered clinical trials, industry payments reported by 30 companies, 3 NIH-funded awards (2004–2008).

  • Most recent indexed publication: 2026 · American journal of hematology
  • Top research focus: Acute Myeloid Leukemia Research
  • 25 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 30 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Leukemia (AML/ALL/CML/CLL)25 trialsMDS / MPN14 trialsLeukemia, Myeloid, Acute8 trialsPrecursor Cell Lymphoblastic Leukemia-Lymphoma2 trialsLeukemia, Promyelocytic, Acute1 trialLeukemia, Lymphoid1 trialMyeloproliferative Disorders1 trial

Research focus

OpenAlex concept fingerprint
Acute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsMyeloproliferative Neoplasms: Diagnosis and TreatmentAcute Lymphoblastic Leukemia researchChronic Lymphocytic Leukemia Research

Drugs & molecules

across trials, industry payments and publications
Venclextageneric · VenetoclaxClinical trials3Industry payments4Publications33Onureggeneric · AzacitidineClinical trials10Industry payments2Publications18DecitabineClinical trials3Industry payments1Publications9

Works with

trial sponsors and companies reporting payments
Celgene CorporationClinical trialsIndustry payments55E.R. Squibb & Sons, L.L.C.Clinical trialsIndustry payments28Taiho Oncology, Inc.Clinical trialsIndustry payments22

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
2,993publications

Distinct works indexed by OpenAlex, matched via ORCID; 190 in PubMed.

90,546citations

Total citations across indexed works.

150h-index

Hirsch index (OpenAlex). i10-index 1,037.

Clinical & industry

trials, payments and federal funding
25clinical trials

Investigator role on registered studies.

View trials
30companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
3NIH grants · 2004–2008

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 25 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

30 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    59.7%
    BCL-2 Inhibitor59.7%
    Venclexta100%
    Part D12 patients
  • Anti-infectives

    40.3%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor22.4%
    Valacyclovir100%
    Part D<11 patients
    Fluoroquinolone Antibacterial17.9%
    Levofloxacin100%
    Part D<11 patients
Where care is delivered (Part B)94.2% facility · 5.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

3 NIH research awards on record, funded 20042008 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/guillermo-garcia-manero-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/guillermo-garcia-manero-md-99420475

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • ResearchGate

    researchgate.net/scientific-contributions/Guillermo-Garcia-Manero-2143705602

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net
3 more verified accounts behind the reveal.Reveal →

Mentions by others

where others cite or feature them
  • Instagram

    instagram.com/aamdsif/reel/CyDZdbps9oh

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com
  • X / Twitter

    twitter.com/leukemiamda

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →twitter.com
  • LinkedIn

    linkedin.com/posts/mdandersoncancercenter_our-dr-guillermo-garcia-manero-and-md-anderson-activity-7102289362859544576-vywT

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
12 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    Medical Oncology, 1999

    2016
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sohoonline.org
  • Active Medical License

    State of Texas, since 2000

    2000
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org
  • Clinical Fellowship

    Hematology and Medical Oncology, Thomas Jefferson University Hospital, Cardeza Foundation and Kimmel Cancer Center, Philadelphia, PA, 1996-1999

    1999
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Board Eligible

    Hematology

    1999
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sohoonline.org
  • Clinical Internship and Residency

    Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, 1993-1996

    1996
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Board Certified

    Internal Medicine

    1996
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sohoonline.org
  • M.D. (Medical Doctor)

    University of Zaragoza School of Medicine, Zaragoza, Spain

    1991
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org

Editorial & leadership roles

journal and society appointments
  • President 2023-2024

    Society of Hematologic Oncology (SOHO); Chair, 2024 SOHO Annual Meeting

    2024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sohoonline.org
  • Chair

    Faculty Senate, The University of Texas MD Anderson Cancer Center, 2020-2021

    2022
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Fellowship Program Director

    Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 2019-present

    2019
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
3 more roles behind the reveal.Reveal →

Highly Cited Researcher

Clarivate's annual list, by award category and year
  • Clinical Medicine
    201520162018201920202024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com

Awards & honors

honors on the public record
10 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
5 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.